A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

G, Chouinard; B, Jones; G, Remington; D, Bloom; D, Addington; GW, MacEwan; A, Labelle; L, Beauclair; W, Arnott

doi:10.1097/00004714-199302000-00004

Public

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Shared by NobleBlocks on Feb 1, 1993 • 12:00 AM UTC

Authors:

Chouinard G

Jones B

Remington G

Abstract

In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, ...

Discussions